Key points from article :
Deep Knowledge Group announces the launch of a new strategic subsidiary, Quant Biomarkers.
Data-driven biomedical analytical company.
Focused on Biotechnology, Precision Longevity Medicine, and novel InsurTech and financial instruments.
Headquarters in Switzerland and branches in the United Kingdom and Germany.
Specialises in the quantitative assessment of Biomarkers of Human Longevity.
The company will also serve as an incubator, IP accelerator, and investment vehicle.
QB will be led by Deep Knowledge Group Managing Partner Dr. Sanja Tomovska, who said "Today's unmet need is in integrated biomarkers data and predictive analysis platforms for intervention decision support in specific therapeutic areas in Longevity."
2023 goal is to introduce biomarker-driven Longevity risk mitigation and intervention support.
